头孢哌酮舒巴坦雾化吸入对慢性阻塞性肺疾病急性加重期患者的疗效

To evaluate the efficacy of cefoperazone and sulbactam in the treatment of patients with chronic obstructive pulmonary disease

目的研究慢性阻塞性肺疾病急性加重期应用头孢哌酮舒巴坦雾化吸入治疗的临床效果和对患者肺功能改善情况。方法将62例慢性阻塞性肺疾病急性加重期的患者作为研究对象,应用随机法将患者分为对照组与研究组,对照组进行常规治疗加痰热清雾化吸入,研究组在对照组治疗的基础上加用头孢哌酮舒巴坦联合雾化吸入。结果研究组在临床疗效以及肺功能情况方面均显著优于对照组(P<0.05)。结论对慢性阻塞性肺疾病急性加重期患者应用常规治疗基础上加用头孢哌酮舒巴坦雾化吸入有助于提升其临床疗效,缓解患者症状。

Objective To study the clinical effect of cefoperazone and sulbactam in the treatment of patients with chronic obstructive pulmonary disease.Methods 62 cases of patients with acute exacerbation of chronic obstructive pulmonary disease were selected as the research objects, and the patients were randomly divided into control group and study group, the control group were given conventional treatment with tanreqing injection , while the study group were treated with cefoperazone and sulbactam on the basis of the theraphy of the control group .Results The clinical efficacy and lung function of the study group were significantly better than the control group(P < 0.05). Conclusion The patients with acute exacerbation of chronic obstructive pulmonary disease treated with sulbactam and cefoperazone can improve the clinical efficacy and relieve the symptoms of the patients, and the application value is significant.